These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 34484294)
1. Integrative Transcriptomic, Lipidomic, and Metabolomic Analysis Reveals Potential Biomarkers of Basal and Luminal Muscle Invasive Bladder Cancer Subtypes. Feng C; Pan L; Tang S; He L; Wang X; Tao Y; Xie Y; Lai Z; Tang Z; Wang Q; Li T Front Genet; 2021; 12():695662. PubMed ID: 34484294 [TBL] [Abstract][Full Text] [Related]
2. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. Benítez R; Yu K; Sirota M; Malats N; Pineda S Front Immunol; 2023; 14():986598. PubMed ID: 36817478 [TBL] [Abstract][Full Text] [Related]
3. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906 [TBL] [Abstract][Full Text] [Related]
5. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971 [TBL] [Abstract][Full Text] [Related]
6. Identification of miR-200c and miR141-Mediated lncRNA-mRNA Crosstalks in Muscle-Invasive Bladder Cancer Subtypes. Liu G; Chen Z; Danilova IG; Bolkov MA; Tuzankina IA; Liu G Front Genet; 2018; 9():422. PubMed ID: 30323832 [TBL] [Abstract][Full Text] [Related]
8. Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. Rinaldetti S; Rempel E; Worst TS; Eckstein M; Steidler A; Weiss CA; Bolenz C; Hartmann A; Erben P Oncotarget; 2018 May; 9(40):25935-25945. PubMed ID: 29899832 [TBL] [Abstract][Full Text] [Related]
9. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523 [TBL] [Abstract][Full Text] [Related]
10. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474 [TBL] [Abstract][Full Text] [Related]
11. Integrating molecular subtype and CD8 Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Liu H; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Zhang W Cancer Immunol Immunother; 2024 Mar; 73(4):66. PubMed ID: 38430246 [TBL] [Abstract][Full Text] [Related]
12. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. de Jong JJ; Boormans JL; van Rhijn BWG; Seiler R; Boorjian SA; Konety B; Bivalacqua TJ; Wheeler T; Svatek RS; Douglas J; Wright J; Dall'Era M; Crabb SJ; Efstathiou JA; van der Heijden MS; Mouw KW; Miyamoto DT; Lotan Y; Black PC; Gibb EA; Porten SP Eur Urol Oncol; 2020 Aug; 3(4):420-423. PubMed ID: 32205136 [TBL] [Abstract][Full Text] [Related]